Uveitis Market Forecast 2034: Statistics, Revenue, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight

(New York, USA) Uveitis Market Summary
In 2022, the Uveitis market across the 7MM was valued at approximately USD 1,468.66 million, with the US contributing the largest share (~USD 759.03 million), driven by increasing prevalence linked to uveitis-associated conditions, heightened disease awareness, and enhanced diagnostic capabilities. Advances in disease classification, multimodal imaging, drug delivery systems, "omics"-based laboratory diagnostics, and ocular immunology have deepened insights into uveitis pathogenesis and susceptibility. Corticosteroids remain the first-line therapy, with immunomodulatory agents employed as steroid-sparing alternatives; surgical interventions like vitrectomy or sustained-release implants are reserved for refractory cases. However, the absence of robust efficacy data for many interventions, coupled with a lack of standardized consensus guidelines across the US, EU4, the UK, and Japan, limits optimal management. Long-term immunosuppressant use, the current gold standard for noninfectious uveitis, is also constrained by significant adverse effects. Consequently, there is an unmet need for rapid-acting, safe therapeutics that also address complications such as macular edema and glaucoma. Emerging agents-including TRS01 (the first potential nonsteroidal topical for noninfectious anterior uveitis), licaminlimab (OCS-02, a topical dual-action biologic), and Roche's vamikibart (RG6179, targeting IL-6 signaling in uveitic macular edema)-are expected to drive market growth through 2034, potentially reshaping the treatment landscape pending regulatory approvals.

DelveInsight's "Uveitis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Uveitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Uveitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Uveitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Uveitis market.

Request for a Free Sample Report @ Uveitis Market Outlook - https://www.delveinsight.com/report-store/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Uveitis Market Report
• In June 2025, AbbVie announced a study is to assess adverse events and effectiveness of adalimumab in Chinese participants requiring high-dose corticosteroids with NIIPPU. Adalimumab is a conditionally approved drug in China used to treat participants with NIIPPU. All participants will receive the same treatment. Approximately 87 adult participants will be enrolled at approximately 15 sites in China.
• In March 2025, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The approval also includes other updates to the label including to the Warnings and Precautions section. As previously announced, the Company plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of diabetic macular edema (DME) in the U.S. ILUVIEN is already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries.
• The total uveitis market size of in the 7MM was approximately USD 1,468 million in 2022 and is projected to increase during the forecast period (2023-2034).
• As per DelveInsight analysis, in 2022, there were approximately 1,009,025 Uveitis diagnosed prevalent cases in the 7MM.
• The total number of Uveitis diagnosed prevalent cases in the US was around 378,281 in 2022.
• The US contributed to the largest Uveitis diagnosed prevalent population, acquiring ~37.5% of the 7MM in 2022. Whereas Spain accounted for the least, with around ~7% of the total population share, respectively, in 2022.
• In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, there were nearly 344,587 cases of NIU, while IU accounted for around 33,695 cases. These numbers are expected to rise during the forecast period due to the rise of overall uveitis infection in the US.
• According to DelveInsight estimates, in EU4 and the UK, based on anatomical location highest cases of uveitis were diagnosed in anterior uveitis, while intermediate uveitis has the least cases. In EU4 and the UK, anterior uveitis accounted for approximately 203,439, followed by 84,154 cases in posterior uveitis, 81,773 cases in pan uveitis, and 46,485 in intermediate uveitis in 2022, which are projected to increase during the forecast period.
• Japan accounted for approximately 214,892 diagnosed prevalent cases of uveitis, out of which nearly 8,039 cases were of HLA-B27-associated uveitis, 17,315 sarcoidosis, 9,894 Behçet's disease, 8,658 Vogt-Koyanagi-Harada disease, 618 JIA, 309 ankylosing spondylitis, 3,092 tuberculosis, 11,749 herpes, 81,628 idiopathic, and 73,589 others cases in 2022. These uveitis cases are expected to change during the forecast period in Japan (2023-2034).
• Leading Uveitis companies working in the market are Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly and Company, Acelyrin, Affibody Medical, Eyevensys, Priovant Therapeutics, Santen Inc, Aerie Pharmaceuticals, Allergan, Bausch Health, Merck, Pfizer Inc, Fera Pharmaceuticals, Teva Pharmaceutical Industries, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Astellas Pharma Inc, Bayer AG, Novartis, and others.
• As per DelveInsight analysis, in 2022, there were approximately 1,009,025 Uveitis diagnosed prevalent cases in the 7MM.
• The total number of Uveitis diagnosed prevalent cases in the US was around 378,281 in 2022.
• Emerging Uveitis therapies such as TRS01, OCS-02, and RG6179 can potentially create a positive shift in the uveitis market size.

Uveitis Overview

Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye, and can lead to vision loss if untreated. Uveitis symptoms typically include eye redness, pain, blurred vision, and sensitivity to light. Uveitis causes range from autoimmune disorders and infections to trauma and idiopathic origins. Uveitis diagnosis involves a comprehensive eye exam, imaging, and sometimes blood tests to determine underlying causes. Uveitis treatment usually includes corticosteroids, immunosuppressive agents, or biologics depending on severity and etiology.

Uveitis types include anterior uveitis (most common), intermediate, posterior, and panuveitis, each affecting different parts of the uveal tract. Uveitis complications can involve glaucoma, cataracts, retinal damage, or permanent vision impairment. Uveitis specialists such as ophthalmologists or uveitis experts play a key role in disease management. Uveitis management focuses on reducing inflammation, preserving vision, and preventing relapses. Uveitis prognosis varies but early detection and proper care improve outcomes significantly.

Uveitis research is advancing, with clinical trials exploring new biologics and targeted therapies. Uveitis awareness is essential to ensure early intervention and reduce the global burden of eye disease. Uveitis care requires long-term monitoring and personalized treatment plans to maintain visual health.

Learn more about Uveitis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Uveitis Treatment Market - https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Uveitis Market

The Uveitis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Uveitis market trends by analyzing the impact of current Uveitis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Uveitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Uveitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The uveitis treatment market is experiencing significant growth, propelled by several key drivers. Foremost among these is the increasing global prevalence of uveitis, often linked to autoimmune diseases, infections, and inflammatory disorders. Advancements in therapeutic options, including biologics and targeted therapies, have enhanced treatment efficacy and patient outcomes. Additionally, heightened awareness of eye health and improved diagnostic techniques have facilitated earlier detection and intervention, further stimulating market expansion.

However, the market faces notable barriers. High treatment costs, particularly associated with advanced biologic therapies, can limit accessibility for some patients. Regulatory challenges and market access issues also pose obstacles to the introduction of new treatments. Moreover, the complexity of uveitis, with its various subtypes and underlying causes, necessitates personalized treatment approaches, complicating standardization and broad application of therapies. Addressing these challenges is crucial for sustaining growth and ensuring that advancements in uveitis treatment translate into improved patient care globally.
According to DelveInsight, the Uveitis market in 7MM is expected to witness a major change in the study period 2020-2034.

Uveitis Epidemiology

The Uveitis epidemiology section provides insights into the historical and current Uveitis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Uveitis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Uveitis Epidemiology @ Uveitis Prevalence - https://www.delveinsight.com/report-store/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Uveitis Marketed Drugs

XIPERE: Clearside Biomedical/Bausch+Lomb
XIPERE, a triamcinolone acetonide injectable suspension, is the first approved medicine delivery via injection for suprachoroidal use to treat macular edema associated with uveitis in the US. Delivering the medicine to the suprachoroidal space (SCS) allows targeted delivery of the therapy with low levels elsewhere in the eye.

YUTIQ/ILUVIEN: EyePoint Pharmaceuticals/Alimera Sciences
YUTIQ is a sterile nonbioerodible intravitreal implant with 0.18 mg fluocinolone acetonide. It releases the drug at an initial rate of 0.25 μg/day in a 36-month sustained-release drug delivery system. YUTIQ contains a corticosteroid and is indicated for treating chronic noninfectious uveitis affecting the posterior segment of the eye. It is preloaded into a single-dose applicator to facilitate the injection of the implant directly into the vitreous. It was approved by the US FDA in October 2018 and launched commercially in February 2019.

Uveitis Emerging Drugs

TRS01: Tarsier Pharma
TRS01, a lead product of Tarsier Pharmaceuticals, first in first-in-class topical immune modulator agent. Dazdotuftide (TRS) is a breakthrough platform technology for treating blinding ocular diseases. TRS was developed to 're-engineer' the immune system. The platform approaches inflammatory diseases from within the system. The technology can effectively treat various autoimmune and inflammatory ocular diseases. TRS01 is a polypeptide conjugate with a dual mechanism of action; the investigational agent induces anti-inflammatory macrophages and inhibits the nuclear factor-kB (Nf-kB) signaling pathway by toll-like receptor 4 (TLR4).

OCS-02 (licaminlimab): Oculis Pharma
OCS-02 (licaminlimab) is a single-chain antibody fragment (scFv) that binds to and neutralizes the activity of human TNFa, with a dual mechanism of action (MoA), anti-inflammation, and anti-necrosis. Unlike full-length monoclonal antibodies, scFv fragments can penetrate ocular surface tissues when used as eye drops due to the smaller molecule size giving it the potential to become the first approved topical biologic for DED (dry eye disease) (OCS-02 was previously known as LME636).

Uveitis Pipeline Development Activities

The Uveitis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Uveitis key players involved in developing targeted therapeutics.

• TRS01: Tarsier Pharma
• Licaminlimab (OCS-02): Oculis Pharma
• Vamikibart (RO720220/RG6179): Roche/Eleven Biotherapeutics
• OLUMIANT (baricitinib): Eli Lilly and Company
• EYS606: Eyevensys
• Izokibep: Acelyrin/Affibody Medical
• Brepocitinib: Priovant Therapeutics (Roivant Sciences and Pfizer)

Request for a sample report to understand more about the Uveitis pipeline development activities @ Uveitis Medication and Companies - https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Uveitis Therapeutics Assessment

Major key companies are working proactively in the Uveitis Therapeutics market to develop novel therapies which will drive the Uveitis treatment markets in the upcoming years are Novartis (SWX: NOVN), AngioDynamics Inc. (NASDAQ: ANGO), Roche (SWX: ROG), Eli Lilly and Company (NYSE: LLY), Acelyrin (NASDAQ: SLRN), Oculis Pharma (NASDAQ: OCS), Santen Inc (TYO: 4536), Aerie Pharmaceuticals (NASDAQ: AERI), Allergan (NYSE: AGN), Bausch Health (NYSE: BHC), Merck (NYSE: MRK), Pfizer Inc (NYSE: PFE), Teva Pharmaceutical Industries (NYSE: TEVA), EyePoint Pharmaceuticals (NASDAQ: EYPT), Astellas Pharma Inc (TYO: 4503), Bayer AG (ETR: BAYN), Tarsier Pharma (TASE: TRSR), and others.

Learn more about the emerging Uveitis therapies & key companies @ Uveitis Clinical Trials and FDA Approvals - https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Uveitis Report Key Insights
1. Uveitis Patient Population
2. Uveitis Market Size and Trends
3. Key Cross Competition in the Uveitis Market
4. Uveitis Market Dynamics (Key Drivers and Barriers)
5. Uveitis Market Opportunities
6. Uveitis Therapeutic Approaches
7. Uveitis Pipeline Analysis
8. Uveitis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Uveitis Market

Table of Contents
1. Key Insights
2. Executive Summary
3. Uveitis Competitive Intelligence Analysis
4. Uveitis Market Overview at a Glance
5. Uveitis Disease Background and Overview
6. Uveitis Patient Journey
7. Uveitis Epidemiology and Patient Population
8. Uveitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Uveitis Unmet Needs
10. Key Endpoints of Uveitis Treatment
11. Uveitis Marketed Products
12. Uveitis Emerging Therapies
13. Uveitis Seven Major Market Analysis
14. Attribute Analysis
15. Uveitis Market Outlook (7 major markets)
16. Uveitis Access and Reimbursement Overview
17. KOL Views on the Uveitis Market
18. Uveitis Market Drivers
19. Uveitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Related Reports:
Uveitis Pipeline
https://www.delveinsight.com/report-store/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Uveitis Pipeline Insight - 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key uveitis companies, including Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, among others.

Autoimmune Uveitis Market
https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Autoimmune Uveitis Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key autoimmune uveitis companies, including Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., among others.

Anterior Uveitis Market
https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Anterior Uveitis Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anterior uveitis companies, including Novartis AG, Santen Pharmaceutical Co., Ltd; AbbVie Inc., Eyegate Pharmaceuticals, Inc., Clearside Biomedical, Inc., Aldeyra Therapeutics, Inc., among others.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/ats-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.